Thursday, March 10, 2011

Genentech's Lucentis works well in trial — but all eyes on NIH study

The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight could come next quarter.

No comments:

Post a Comment